Reducing the global burden of HTLV-1 infection: An agenda for research and action
Open accessAbstract
Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are three modes of HTLV-1 transmission between hosts: parenteral, vertical, and sexual.
“There are three modes of transmission between hosts: parenteral transmission (blood and blood products), vertical transmission (during breastfeeding or parturition), and sexual transmission [62].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [62]
The Introduction identifies mother-to-child, sexual, contaminated-blood-product, and needle-sharing transmission; section 3.1 specifically identifies breastfeeding, blood transfusion, and sexual intercourse. These support the three broad categories in the citing sentence, but our copy does not specify transmission during parturition or state that the categories are exhaustive. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Martínez, J. L. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00001 · Cited by 2,101 · see citing works
Epidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428 · see citing works
Self-citationHuman T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
Matsuoka, M., & Jeang, K.-T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2111 · Cited by 829 · see citing works
Self-citationIntegrated molecular analysis of adult T cell leukemia/lymphoma
Kataoka, K., Nagata, Y., Kitanaka, A., Shiraishi, Y., Shimamura, T., Yasunaga, J., Totoki, Y., Chiba, K., Sato‐Otsubo, A., Nagae, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3415 · Cited by 819 · see citing works
Self-citationTsukasaki, K., Hermine, O., Bazarbachi, A. A., Ratner, L., Ramos, J. C., Harrington, W. J., O’Mahony, D., Janik, J. E., Bittencourt, A. L., Taylor, G. P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2428 · Cited by 557 · see citing works
Self-citationEpidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases
Gonçalves, D. U., Proietti, F. A., Ribas, J. G. R., Araújo, M. G., Pinheiro, S. R., Guedes, A. C., & Carneiro-Proietti, A. B. F. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00063-09 · Cited by 478 · see citing works
Self-citationBazarbachi, A. A., Plumelle, Y., Ramos, J. C., Tortevoye, P., Otrock, Z. K., Taylor, G. P., Antoine Gessain, A., Harrington, W. J., Panelatti, G., & Hermine, O. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0669 · Cited by 372 · see citing works
Self-citationYamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato‐Otsubo, A., Muto, S., Utsunomiya, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.015 · Cited by 325 · see citing works
Self-citationGillet, N. A., Malani, N., Melamed, A., Gormley, N. A., Carter, R., Bentley, D., Berry, C. C., Bushman, F. D., Taylor, G. P., & Bangham, C. R. M. (2011) · Blood · doi:10.1182/blood-2010-10-312926 · Cited by 317 · see citing works
Self-citationHTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araújo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 277 · see citing works
Self-citationGabet, A., Mortreux, F., Talarmin, A., Plumelle, Y., Leclercq, I., Leroy, A., Antoine Gessain, A., Clity, E., Joubert, M., & Wattel, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203870 · Cited by 151 · see citing works
Pathways of cell-cell transmission of HTLV-1
Pique, C., & Jones, K. S. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00378 · Cited by 148 · see citing works
Inflammatory manifestations of HTLV-1 and their therapeutic options
Martin, F., Taylor, G. P., & Jacobson, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.966690 · Cited by 148 · see citing works
Self-citationSuehiro, Y., Hasegawa, A., Iino, T., Sasada, A., Watanabe, N., Matsuoka, M., Takamori, A., Tanosaki, R., Utsunomiya, A., Choi, I., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13302 · Cited by 125 · see citing works
Self-citationGillet, N. A., Gutiérrez, G., Rodríguez, S., de Brogniez, A., Renotte, N., Álvarez, I., Trono, K. G., & Willems, L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003687 · Cited by 96 · see citing works
Self-citationMurphy, E. L. (2016) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2015.12.001 · Cited by 96 · see citing works
Self-citationFilippone, C., Betsem, E., Tortevoye, P., Cassar, O., Bassot, S., Froment, A., Fontanet, A. L., & Antoine Gessain, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ145 · Cited by 85 · see citing works
Sibon, D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27198 · Cited by 79 · see citing works
Tsukasaki, K., & Tobinai, K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0572 · Cited by 76 · see citing works
Current concepts regarding the HTLV-1 receptor complex
Ghez, D., Lepelletier, Y., Jones, K. S., Pique, C., & Hermine, O. (2010) · Retrovirology · doi:10.1186/1742-4690-7-99 · Cited by 73 · see citing works
Self-citationVaccination against δ-Retroviruses: The Bovine Leukemia Virus Paradigm
Gutiérrez, G., Rodríguez, S., de Brogniez, A., et al. (2014) · Viruses · doi:10.3390/v6062416 · Cited by 69 · see citing works
Calattini, S., Chevalier, S. A., Duprez, R., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00799-06 · Cited by 69 · see citing works
How does HTLV-I persist despite a strong cell-mediated immune response?
Asquith, B., & Bangham, C. R. M. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.006 · Cited by 64 · see citing works
Self-citationSafety of long-term treatment of HAM/TSP patients with valproic acid
Olindo, S., Belrose, G., Gillet, N., Rodriguez, S., Boxus, M., Verlaeten, O., Asquith, B., Bangham, C., Signaté, A., Smadja, D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-349910 · Cited by 52 · see citing works
Self-citationKchour, G., Rezaee, S. A., Farid, R., Ghantous, A., Rafatpanah, H., Tarhini, M., Kooshyar, M. M., Hajj, H. E., Berry, F., Mortada, M., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-91 · Cited by 45 · see citing works
Self-citationRecent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
Kato, K., & Akashi, K. (2015) · Viruses · doi:10.3390/v7122960 · Cited by 41 · see citing works
de Brogniez, A., Bouzar, A. B., Jacques, J.-R., Cosse, J.-P., Gillet, N. A., Callebaut, I., Reichert, M., & Willems, L. (2015) · Journal of Virology · doi:10.1128/jvi.00261-15 · Cited by 37 · see citing works
Self-citationThe Global Virus Network: Challenging chikungunya
McSweegan, E. F., Weaver, S. C., Lecuit, M., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.003 · Cited by 35 · see citing works
Boxus, M., Twizere, J., Legros, S., Kettmann, R., & Willems, L. (2011) · Blood · doi:10.1182/blood-2011-05-356790 · Cited by 30 · see citing works
Self-citationRichard, L., Mouinga‐Ondémé, A., Betsem, E., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw389 · Cited by 30 · see citing works
Development of neurologic diseases in a patient with primate T lymphotropic virus type 1 (PTLV-1)
Enose‐Akahata, Y., Caruso, B. P., Haner, B., et al. (2016) · Retrovirology · doi:10.1186/s12977-016-0290-9 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22 · see citing works
- Authors
- Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., Carneiro-Proietti, A. B. D. F., Cheng, H., Chieco-Bianchi, L., Ciminale, V., Coelho-dos-Reis, J., Esparza, J., Gallo, R. C., Gessain, A., Gotuzzo, E., Hall, W., Harford, J., Hermine, O., Jacobson, S., Macchi, B., Macpherson, C., Mahieux, R., Matsuoka, M., Murphy, E., Peloponese, J.-M., Simon, V., Tagaya, Y., Taylor, G. P., Watanabe, T., & Yamano, Y.
- Affiliations
- University of Liège (BE)
- Global Virus Network (US)
- University of Insubria (IT)
- Imperial College London (GB)
- American University of Beirut (LB)
- University of Verona (IT)
- University of Padua (IT)
- Fiocruz Minas (BR)
- Instituto de Medicina Tropical Alexander von Humboldt (PE)
- National Institutes of Health (US)
- Hôpital Necker-Enfants Malades (FR)
- National Institute of Neurological Disorders and Stroke (US)
- University of Rome Tor Vergata (IT)
- St. George's University (GD)
- École Normale Supérieure de Lyon (FR)
- Kyoto University (JP)
- University of California, San Francisco (US)
- Icahn School of Medicine at Mount Sinai (US)
- The University of Tokyo (JP)
- St. Marianna University School of Medicine (JP)
- Corresponding author
- Willems, Luc
- ORCID
- Willems, Luc
- Hasegawa, Hideki
- Accolla, Roberto
- Bangham, Charles
- Bazarbachi, Ali
- Bertazzoni, Umberto
- Cheng, Hua
- Ciminale, Vincenzo
- Coelho-dos-Reis, Jordana
- Esparza, José
- Gallo, Robert C.
- Gotuzzo, Eduardo
- Hall, William
- Hermine, Olivier
- Jacobson, Steven
- Macchi, Beatrice
- Macpherson, Calum
- Mahieux, Renaud
- Matsuoka, Masao
- Murphy, Edward
- Peloponese, Jean-Marie
- Simon, Viviana
- Tagaya, Yutaka
- Taylor, Graham P.
- Watanabe, Toshiki
- Yamano, Yoshihisa
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 137
- Pages
- 41-48
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2555145663
- Cited by
- 140
- References
- 31
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 15 · 2022: 15 · 2021: 15 · 2020: 21 · 2019: 15 · 2018: 20 · 2017: 14
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antiviral Research (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- HAL (submittedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
- Funders
- Fonds National de la Recherche Scientifique
- Télévie
- Belgian Science Policy Office
- Belgian Foundation against Cancer (FBC),
- Centre anticancéreux près ULg
- Fonds Léon Fredericq
- Gembloux Agrobiotech (GxABT)
- ULg Fonds Spéciaux pour la Recherche
- Service Public Fédéral
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- HTLV-1, adult T-cell leukemia/lymphoma, antiretroviral therapy, prophylactic vaccines, therapeutic vaccines, research agenda
- MeSH terms
- Humans, Spinal Cord Diseases, Global Health, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections, Paraparesis, Tropical Spastic, HIV Infections, Cost of Illness, Advisory Committees, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
